Tazemetostat in Relapsed/Refractory Follicular Lymphoma: A Propensity Score–Matched Analysis of E7438-G000-101 Trial Outcomes

home / between-the-lines / tazemetostat-in-rrfl-a-propensity-score-matched-analysis-of-e7438-g000-101-trial-outcomes

Expert hematologist-oncologists share insight on the E7438-G000-101 clinical trial and consider use of tazemetostat, an EZH2 inhibitor, in relapsed/refractory follicular lymphoma.